FrancophonIA/ELRC3.0 huggingface dataset:
English: Pemetrexed Krka 100 mg powder for concentrate for solution for infusion Reconstitute 100 mg vials with 4.2 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Slovenian: Pemetreksed Krka 100 mg prašek za koncentrat za raztopino za infundiranje 100 mg viale pripravite s 4,2 ml 9 mg/ml (0,9 %) raztopine natrijevega klorida za injiciranje brez konzervansa, tako dobite raztopino, ki vsebuje 25 mg/ml pemetrekseda.
English: Stomatitis/Pharyngitis Nausea
Slovenian: Diareja Bruhanje Stomatitis/ faringitis Slabost Anoreksija
English: Each vial contains 100 mg pemetrexed (as pemetrexed disodium hemipentahydrate).
Slovenian: Ena viala vsebuje 100 mg pemetrekseda (v obliki dinatrijevega pemetreksedata hemipentahidrata).
English: pemetrexed/ Cisplatin (N=168)
Slovenian: Pemetreksed/cisplatin (N = 168)
English: These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥ CTC Grade 2 bleeding.
Slovenian: 50 % predhodnega odmerka (zdravila Pemetreksed Krka in cisplatina) Ta merila ustrezajo definiciji krvavitve stopnje 2 ali več v skladu s skupnimi merili toksičnosti (CTC) Nacionalnega inštituta za rakava obolenja (National Cancer Institute Common Toxicity Criteria, CTC v2.0; NCI 1998).
English: Pemetrexed Krka 500 mg powder for concentrate for solution for infusion pemetrexed
Slovenian: Pemetreksed Krka 500 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
English: Each vial contains 500 mg pemetrexed (as pemetrexed disodium hemipentahydrate).
Slovenian: Ena viala vsebuje 500 mg pemetrekseda (v obliki dinatrijevega pemetreksedata hemipentahidrata).
English: Warnings and precautions Talk to your doctor or hospital pharmacist before using Pemetrexed Krka.
Slovenian: Pred začetkom uporabe zdravila Pemetreksed Krka se posvetujte z zdravnikom ali bolnišničnim farmacevtom.
English: ≥ 50,000/mm
Slovenian: 3 in najnižje število trombocitov  50.000 /mm
English: Gastrointestinal disorders
Slovenian: Docetaksel sistem
English: Leukocytes decreased Haemoglobin decreased 26.2 Platelets decreased
Slovenian: Znižani nevtrofilci/ granulociti Znižani levkociti Znižan hemoglobin Znižani trombociti
English: The median OS for patients with NSCLC other than predominantly squamous cell histology (N=481) was 15.5 months for the pemetrexed arm and 10.3 months for the placebo arm, hazard ratio = 0.70 (95% CI=0.56-0.88, p=0.002).
Slovenian: Za bolnike z NSCLC , ki nima pretežno ploščatocelične histologije (N = 430, neodvisno pregledana populacija) je bila mediana preživetja brez napredovanja 4,4 meseca za skupino s pemetreksedom in 1,8 meseca za skupino s placebom, razmerje tveganja = 0,47, 95 % IZ = 0,37-0,60, p = 0,00001).
English: National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998)
Slovenian: Vnetje sluznice stopnje 3 ali 4 50 % predhodnega odmerka 100 % predhodnega odmerka Skupna merila toksičnosti Nacionalnega inštituta za rakava obolenja (CTC v2.0; NCI 1998) Brez nevrološke toksičnosti
English: How to use Pemetrexed Krka
Slovenian: Kako uporabljati zdravilo Pemetreksed Krka
English: Rash/desquamation
Slovenian: Izpuščaj/ luščenje
English: Neutrophils/Granulocytes decreased
Slovenian: Znižani nevtrofilci/ granulociti Znižani levkociti Znižan hemoglobin
English: ANC
Slovenian: EXP
English: Pemetrexed Krka 100 mg powder for concentrate for solution for infusion pemetrexed
Slovenian: Pemetreksed Krka 100 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
English: Common Renal disorders**** 7.6
Slovenian: Bolezni sečil****
English: Pemetrexed Krka 500 mg powder for concentrate pemetrexed
Slovenian: Pemetreksed Krka 500 mg prašek za koncentrat pemetreksed i.v.
English: Excluding neurotoxicity
Slovenian: Nevropatijasenzorična
English: For precautions to be taken before handling or administering Pemetrexed Krka, see section 6.6.
Slovenian: Za previdnostne ukrepe, potrebne pred ravnanjem z zdravilom ali dajanjem zdravila glejte poglavje
English: Pemetrexed Krka 100 mg powder for concentrate pemetrexed
Slovenian: Pemetreksed Krka 100 mg prašek za koncentrat pemetreksed i.v.
English: Oesophagitis/radiation oesophagitis has been uncommonly reported during clinical trials with pemetrexed:
Slovenian: V kliničnih preskušanjih s pemetreksedom so občasno poročali o ezofagitisu/radiacijskem ezofagitisu.
English: Pemetrexed/Cisplati n (N=839)
Slovenian: Pogostnost Dogodek** Pemetreksed/ cisplatin (N = 839)
English: Further information on Loxicom can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/loxicom.
Slovenian: Nadaljnje informacije o zdravilu Loxicom so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPAR/loxicom
English: Loxicom received a marketing authorisation valid throughout the EU on 10 February 2009.
Slovenian: Zdravilo Loxicom je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 10. februarja 2009.
English: Loxicom (meloxicam)
Slovenian: Loxicom (meloksikam)
English: An overview of Loxicom and why it is authorised in the EU
Slovenian: Pregled zdravila Loxicom in zakaj je odobreno v EU
English: Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Metacam, and do not need to be repeated for Loxicom.
Slovenian: Študije o koristih in tveganjih učinkovine pri odobrenih načinih uporabe so že bile izvedene z referenčnim zdravilom Metacam, zato jih ni treba ponoviti za zdravilo Loxicom.
English: Loxicom is an anti-inflammatory medicine used in cattle, pigs, horses, dogs and cats.
Slovenian: Loxicom je protivnetno zdravilo, ki se uporablja za zdravljenje goveda, prašičev, konjev, psov in mačk.
English: For the 20 mg/ml solution for injection the meat withdrawal period is five days, and for the 50 mg/ml oral paste it is three days.
Slovenian: Pri uporabi 20 mg/ml raztopine za injiciranje je karenca za meso pet dni, pri uporabi 50 mg/ml peroralne paste pa tri dni.
English: Why is Loxicom authorised in the EU?
Slovenian: Zakaj je zdravilo Loxicom odobreno v EU?
English: The European Medicines Agency concluded that, in accordance with EU requirements, Loxicom has been shown to have comparable quality and to be bioequivalent to Metacam.
Slovenian: Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Loxicom primerljivo raven kakovosti in je bioekvivalentno zdravilu Metacam.
English: What are the benefits and risks of Loxicom?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Loxicom?
English: As for every medicine, the company provided studies on the quality of Loxicom.
Slovenian: Tako kot za vsako zdravilo je podjetje predložilo študije o kakovosti zdravila Loxicom.
English: What is Loxicom and what is it used for?
Slovenian: Kaj je zdravilo Loxicom in za kaj se uporablja?
English: Because Loxicom is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Loxicom generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: This means that Loxicom contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Metacam.
Slovenian: To pomeni, da vsebuje enako učinkovino in ima enak način delovanja kot referenčno zdravilo Metacam, ki je že odobreno v Evropski uniji (EU).
English: Other information about Loxicom
Slovenian: Druge informacije o zdravilu Loxicom
English: Loxicom contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Slovenian: Zdravilo Loxicom vsebuje meloksikam, ki spada v skupino zdravil, imenovanih nesteroidna protivnetna zdravila (NSAID).
English: For further information about using Loxicom, see the package leaflet or contact your veterinarian or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Loxicom glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Loxicom, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Slovenian: V povzetek glavnih značilnosti zdravila Loxicom in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
English: The formulation and dose to use depends on the animal and the condition being treated.
Slovenian: Formulacija in odmerek sta odvisna od zdravljene živali in vrste bolezni, ki se zdravi.
English: In pigs, Loxicom is used to reduce lameness and inflammation in non-infectious locomotor disorders (diseases that affect the ability to move that are not caused by an infection) and to support together with appropriate antibiotic therapy the treatment of diseases that occur after farrowing (giving birth) such as puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome).
Slovenian: Pri prašičih se zdravilo Loxicom uporablja za zmanjšanje šepavosti in vnetja pri neinfektivnih lokomotornih obolenjih (boleznih, ki prizadenejo gibalne sposobnosti živali, ki niso posledica okužbe) in v kombinaciji z ustreznimi antibiotiki kot podpora pri zdravljenju bolezni po oprasitvi (kotitvi mladičev), kot so puerperalna septikemija in toksemija (sindrom mastitis-metritis-agalaktija).
English: It can be used to relieve pain following dehorning in calves and to support the treatment of acute mastitis (inflammation of the udder), in combination with antibiotics.
Slovenian: Lahko se uporablja za lajšanje bolečin po odstranitvi rogov pri teletih in kot podpora zdravljenju akutnega mastitisa (vnetja vimena) v kombinaciji z antibiotiki.
English: In cattle, Loxicom is used together with appropriate antibiotic therapy, to reduce clinical signs of acute respiratory infection (infection of the lungs and airways).
Slovenian: Pri govedu se zdravilo Loxicom uporablja skupaj z ustreznim antibiotičnim zdravljenjem za zmanjšanje kliničnih znakov akutne okužbe dihal (okužbe pljuč in dihalnih poti).
English: Moreover, it is used to lessen inflammation and pain in musculoskeletal disorders.
Slovenian: Poleg tega se uporablja tudi za zmanjšanje vnetja in lajšanje bolečin pri kostno-mišičnih obolenjih.
English: It can be used with oral re-hydration therapy (fluids given by mouth to restore water levels in the body) to reduce diarrhoea in calves of over one week of age and young, non-lactating cattle.
Slovenian: Uporablja se lahko tudi s peroralno rehidracijo (tekočinami, ki jih žival zaužije peroralno za vzpostavitev ustrezne ravni vode v telesu) za zmanjševanje driske pri teletih, starejših od enega tedna, ter pri mladem govedu zunaj obdobja laktacije.
English: As prostaglandins trigger inflammation, pain, exudation (fluid that leaks out of blood vessels during an inflammation) and fever, meloxicam reduces these signs of disease.
Slovenian: Prostaglandini sprožajo vnetje, bolečino in izcejanje tekočine (izcejanje tekočine iz krvnih žil med vnetnim procesom) ter povišano telesno temperaturo, meloksikam pa te bolezenske znake zmanjšuje.
English: Loxicom contains the active substance meloxicam and is a ‘generic medicine'.
Slovenian: Zdravilo Loxicom vsebuje učinkovino meloksikam in je generično zdravilo.
English: In horses, Loxicom is used to reduce pain associated with colic (abdominal pain) and to lessen inflammation and relieve pain in acute and chronic musculo-skeletal disorders (disorders affecting the muscles and bones).
Slovenian: Pri konjih se zdravilo Loxicom uporablja za lajšanje bolečin, povezanih s kolikami (trebušnih bolečin), ter zmanjšanje vnetja in lajšanje bolečin pri akutnih in kroničnih kostno-mišičnih obolenjih (obolenjih, ki prizadenejo mišice in kosti).
English: Therefore, the Agency's view was that, as for Metacam, the benefit of Loxicom outweighs the identified risk and it can be authorised for use in the EU.
Slovenian: Zato je menila, da koristi zdravila Loxicom enako kot pri zdravilu Metacam odtehtajo znana tveganja in da se zdravilo lahko odobri v EU.
English: Loxicom is available as an oral (taken by mouth) suspension, oral paste, chewable tablets and a solution for injection.
Slovenian: Zdravilo Loxicom je na voljo v obliki peroralne suspenzije, peroralne paste, žvečljivih tablet in raztopine za injiciranje.
English: How has Loxicom been studied?
Slovenian: Kako je bilo zdravilo Loxicom raziskano?
English: How does Loxicom work?
Slovenian: Kako zdravilo Loxicom deluje?
English: In cats, Loxicom is used to reduce pain and inflammation after ovariohysterectomy (spaying operation), orthopaedic and minor soft tissue surgery.
Slovenian: Pri mačkah se zdravilo Loxicom uporablja za lajšanje bolečin in zmanjšanje vnetja po ovariohisterektomiji (odstranitvi rodil), ortopedskih kirurških posegih in manjših kirurških posegih na mehkih tkivih.
English: How is Loxicom used?
Slovenian: Kako se zdravilo Loxicom uporablja?
English: Loxicom can only be obtained with a prescription.
Slovenian: Predpisovanje in izdaja zdravila Loxicom je le na recept.
English: In dogs, Loxicom is used to reduce pain and inflammation following orthopaedic (e.g. fracture operation) and soft tissue surgery.
Slovenian: Pri psih se zdravilo Loxicom uporablja za lajšanje bolečin in zmanjšanje vnetja po ortopedskih kirurških posegih (npr. kirurškem posegu zaradi zloma kosti) in kirurških posegih na mehkih tkivih.
English: The precautions are the same as for the reference medicine since Loxicom is a generic medicine.
Slovenian: Ker je zdravilo Loxicom generično zdravilo, so previdnostni ukrepi enaki kot pri referenčnem zdravilu.
English: h-4197-AA-en
Slovenian: h-4197-AA-sl
English: The average length of response was 8.3 months.
Slovenian: Povprečno trajanje odziva je bilo 8,3 meseca.
English: Further information on Zykadia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije za zdravilo Zykadia so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This was switched to full marketing authorisation on 26 July 2017.
Slovenian: To je bilo 26. julija 2017 spremenjeno v običajno dovoljenje za promet.
English: The recommended dose is 450 mg (3 capsules) once a day taken with food at the same time each day.
Slovenian: Priporočeni odmerek je 450 mg (tri kapsule) enkrat na dan vedno ob istem času.
English: In the second study, the overall response rate was 41% (57 of 140 patients) and the average length of response was 10.6 months.
Slovenian: V drugi študiji je bila splošna odzivna stopnja 41 % (57 od 140 bolnikov), povprečno trajanje odziva pa 10,6 meseca.
English: As the company has supplied the additional information necessary, the authorisation has been switched from conditional to full approval.
Slovenian: Ker je podjetje predložilo dodatne zahtevane podatke, je bilo dovoljenje za promet spremenjeno iz pogojnega v običajno.
English: What measures are being taken to ensure the safe and effective use of Zykadia?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zykadia?
English: In two of these studies, involving 303 patients, the medicine was not compared with any other treatment.
Slovenian: v dveh od teh študij, ki sta vključevali 303 bolnike, zdravila niso primerjali z nobenim drugim zdravljenjem.
English: The European Medicines Agency therefore decided that Zykadia's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Zykadia večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
English: Zykadia received a conditional marketing authorisation valid throughout the EU on 06 May 2015.
Slovenian: Za zdravilo Zykadia je bilo 6. maja 2015 izdano pogojno dovoljenje za promet, veljavno po vsej EU.
English: Other information about Zykadia
Slovenian: Druge informacije o zdravilu Zykadia
English: Zykadia was originally given ‘conditional approval' because there was more evidence to come about the medicine.
Slovenian: Zdravilo Zykadia je prvotno pridobilo „pogojno dovoljenje za promet“, ker je bilo pričakovanih še več dokazov o zdravilu.
English: Response to treatment was assessed using body scans and standardised criteria used for solid tumours, with complete response being when the patient had no remaining signs of the cancer.
Slovenian: Odziv na zdravljenje so ocenjevali s slikanjem telesa in standardiziranimi merili, ki se uporabljajo za čvrste tumorje; popoln odziv je pri tem pomenil, da bolnik nima nikakršnih preostalih znakov raka.
English: An overview of Zykadia and why it is authorised in the EU
Slovenian: Pregled zdravila Zykadia in zakaj je odobreno v EU
English: The presence of genetic defects affecting ALK (‘ALK-positive' status) has to be confirmed in advance by appropriate methods.
Slovenian: Prisotnost genskih okvar, ki vplivajo na anaplastično limfomsko kinazo (ALK-pozitivno stanje), je treba predhodno potrditi z ustreznimi metodami.
English: As for all medicines, data on the use of Zykadia are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Zykadia stalno spremljajo.
English: What benefits of Zykadia have been shown in studies?
Slovenian: Kakšne koristi zdravila Zykadia so se pokazale v študijah?
English: In one study 56% of patients given Zykadia (92 of 163) were considered by the treating doctors to have shown a complete or partial response to the medicine.
Slovenian: V eni študiji so zdravniki za približno 56 % bolnikov, ki so prejemali zdravilo Zykadia (92 od 163), presodili, da so dosegli popoln ali delen odziv na zdravilo.
English: What is Zykadia and what is it used for?
Slovenian: Kaj je zdravilo Zykadia in za kaj se uporablja?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zykadia have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Zykadia upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: The most common side effects with Zykadia (which may affect 1 or more people in 10) are diarrhoea, nausea (feeling sick), vomiting, tiredness, abnormal liver tests, abdominal (belly) pain, decreased appetite, weight loss, constipation, rash, increases in the level of a waste product called creatinine in the blood (a possible sign of kidney problems), oesophageal disorder (problems affecting the food pipe) and anaemia (low levels of red blood cells).
Slovenian: Najpogostejši neželeni učinki zdravila Zykadia (ki se lahko pojavijo pri 1 ali več od 10 bolnikov) so driska, navzea (siljenje na bruhanje), bruhanje, utrujenost, nenormalni rezultati jetrnih testov, bolečine v trebuhu, zmanjšan tek, izguba telesne mase, zaprtje, izpuščaji, povečane ravni odpadnega produkta, imenovanega kreatinin, v krvi (možen pokazatelj težav z ledvicami), motnje požiranja (težave s požiralnikom) in anemija (nizke ravni rdečih krvničk).
English: Side effects reported with Zykadia are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Zykadia, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: In the third study in 231 patients, Zykadia was compared with standard chemotherapy (medicines to treat cancer).
Slovenian: V tretji študiji, ki je zajela 231 bolnikov, so zdravilo Zykadia primerjali s standardno kemoterapijo (zdravili za zdravljenje raka).
English: What are the risks associated with Zykadia?
Slovenian: Kakšna tveganja so povezana z zdravilom Zykadia?
English: Why is Zykadia authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Zykadia odobreno v EU?
English: For more information about using Zykadia, see the package leaflet or contact a doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Zykadia glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Regarding safety, the adverse effects with Zykadia generally appeared manageable.
Slovenian: Kar zadeva varnost, so neželeni učinki zdravila Zykadia na splošno obvladljivi.
English: The doctor may decide to reduce the dose or stop treatment temporarily if side effects occur.
Slovenian: V primeru neželenih učinkov bo zdravnik morda zmanjšal odmerek ali začasno prekinil zdravljenje.
English: Zykadia can only be obtained with a prescription and treatment must be started and supervised by a doctor who is experienced in using cancer medicines.
Slovenian: Predpisovanje in izdaja zdravila Zykadia je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil proti raku.
English: The most common severe reactions (which may affect 1 or more people in 20) are abnormal liver tests, tiredness, diarrhoea, nausea, vomiting and hyperglycaemia (high blood sugar).
Slovenian: Najpogostejši neželeni učinki (ki se lahko pojavijo pri 1 ali več od 20 bolnikov) so nenormalni rezultati jetrnih testov, utrujenost, driska, slabost, bruhanje in hiperglikemija (povišan sladkor v krvi).
English: Zykadia has been shown to be effective at treating patients whose disease progressed during or shortly after treatment with crizotinib and who currently have very limited treatment options, as well as patients who have not been treated before.
Slovenian: Zdravilo Zykadia se je izkazalo za učinkovito pri zdravljenju bolnikov, katerih bolezen je napredovala med zdravljenjem s krizotinibom ali kmalu po njem in ki trenutno nimajo na razpolago veliko možnosti zdravljenja, ter pri zdravljenju bolnikov, ki predhodno še niso bili zdravljeni.
English: Zykadia is a cancer medicine used on its own to treat adults with a type of lung cancer called nonsmall-cell lung cancer (NSCLC), when the disease is advanced.
Slovenian: Zykadia je zdravilo, ki se uporablja za zdravljenje odraslih z vrsto pljučnega raka, imenovano nedrobnocelični pljučni rak (NSCLC), pri katerih je bolezen napredovala.
English: It is only used if the NSCLC is ‘ALKpositive', which means that the cancer cells have certain defects affecting the gene responsible for a protein called ALK (anaplastic lymphoma kinase).
Slovenian: Uporablja se le, če je nedrobnocelični pljučni rak ALK-pozitiven, kar pomeni, da imajo rakave celice določene okvare, ki vplivajo na gen, odgovoren za beljakovino ALK (anaplastična limfomska kinaza).
English: ALK belongs to a family of proteins called receptor tyrosine kinases, which are involved in the growth of cells and the development of new blood vessels that supply them.
Slovenian: Anaplastična limfomska kinaza spada v skupino beljakovin, imenovanih receptorji tirozin-kinaze, ki sodelujejo pri rasti celic in razvoju novih krvnih žil, ki te celice oskrbujejo.
English: Patients given Zykadia lived for an average of 16.6 months without their disease getting worse compared with 8.1 months in patients given standard chemotherapy.
Slovenian: Bolniki, ki so prejemali zdravilo Zykadia, so živeli povprečno 16,6 meseca brez poslabšanja bolezni, bolniki, ki so prejemali standardno kemoterapijo, pa 8,1 meseca.
English: Zykadia has been shown to be effective at treating advanced, ALK-positive NSCLC in three main studies in patients whose disease progressed despite previous treatment with the medicine crizotinib:
Slovenian: Zdravilo Zykadia se je izkazalo za učinkovito pri zdravljenju napredovalega ALK-pozitivnega nedrobnoceličnega pljučnega raka v treh glavnih študijah pri bolnikih, katerih bolezen je napredovala kljub predhodnemu zdravljenju s krizotinibom: